Intercept Pharmaceuticals (BMV:ICPT *) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ICPT * Panoramica delle azioni

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.

Informazioni sull'azienda

ICPT * analisi fondamentale
Punteggio fiocco di neve
Valutazione	4/6
Crescita futura	4/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Negoziato a 36.7% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 63.85% all'anno

Analisi del rischio

Le azioni sono altamente illiquide

Gli azionisti sono stati diluiti nell'ultimo anno

Intercept Pharmaceuticals, Inc. Concorrenti

Genomma Lab Internacional. de

BMV:LAB B

Mex$23.6b

Cutia Therapeutics

SEHK:2487

HK$3.7b

Shanghai OPM Biosciences

SHSE:688293

CN¥3.5b

NatureCellLtd

KOSDAQ:A007390

₩592.7b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Intercept Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$329.00
Massimo di 52 settimane	US$0
Minimo di 52 settimane	US$0
Beta	1.27
1Variazione di 1 mese	0%
Variazione a 3 mesi	0%
Variazione di 1 anno	0%
3Variazione a 3 anni	-83.98%
Variazione a 5 anni	n/a
Variazione dall'IPO	-78.86%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	ICPT *	MX Biotechs	MX Mercato
7D	0%	0%	0%
1Y	0%	0%	0%

Ritorno vs Industria: ICPT * ha superato il MX Biotechs che ha restituito 9.1 % nell'ultimo anno.

Rendimento vs Mercato: ICPT * ha avuto una performance inferiore al mercato MX che ha registrato un rendimento 2.4 % nell'ultimo anno.

Volatilità dei prezzi

Is ICPT *'s price volatile compared to industry and market?
ICPT * volatility
ICPT * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Prezzo delle azioni stabile: ICPT * non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di ICPT * nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2002	341	Jerry Durso	www.interceptpharma.com

Intercept Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Intercept Pharmaceuticals con la sua capitalizzazione di mercato?
ICPT * statistiche fondamentali
Capitalizzazione di mercato	Mex$8.54b
Guadagni(TTM)	-Mex$3.00b
Ricavi(TTM)	Mex$5.09b

1.7x

Rapporto P/S

-2.9x

Rapporto P/E

ICPT * è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ICPT * Conto economico (TTM)
Ricavi	US$294.52m
Costo del fatturato	US$983.00k
Profitto lordo	US$293.54m
Altre spese	US$466.84m
Guadagni	-US$173.30m

Ultimi guadagni dichiarati

Mar 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-4.16
Margine lordo	99.67%
Margine di profitto netto	-58.84%
Rapporto debito/patrimonio netto	495.7%

Come si è comportato ICPT * nel lungo periodo?

Vedi performance storica e confronto

ICPT * Panoramica delle azioni

Premi

Analisi del rischio

Intercept Pharmaceuticals, Inc. Concorrenti

BMV:LAB B

Mex$23.6b

SEHK:2487

HK$3.7b

SHSE:688293

CN¥3.5b

KOSDAQ:A007390

₩592.7b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Recent updates

Intercept Pharmaceuticals, Inc. Provides Regulatory Update Regarding sNDA for OCALIVA

Intercept Announces Statement on FDA Advisory Committee Meeting

Intercept Presents New Sub-Analyses of Phase 3 Poise Data Showcasing the Effect of Oca on Key Liver Biomarkers in Patients with PBC at EASL Congress 2024

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021)

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Second quarter 2022 earnings released: US$0.68 loss per share (vs US$0.33 loss in 2Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Forecast breakeven date moved forward to 2022

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Intercept Pharmaceuticals, Inc. Riepilogo dei fondamenti

1.7x

-2.9x

Guadagni e ricavi